SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3b2r'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1BZM_A_MZMA262_1 (CARBONIC ANHYDRASE I)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	PHE A 820 HIS A 653 THR A 621 HIS A 617	VDN A 1 (-3.6A) None None None	0.97A	1bzmA-3b2rA: undetectable	1bzmA-3b2rA: 20.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EI6_A_PPFA410_1 (PHOSPHONOACETATE HYDROLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	THR A 723 ASP A 654 HIS A 613 HIS A 684	None None VDN A 1 (-4.3A) None	0.99A	1ei6A-3b2rA: undetectable	1ei6A-3b2rA: 22.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FML_B_RTLB501_0 (RETINOL DEHYDRATASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ILE A 716 LEU A 651 SER A 652 LEU A 701 ILE A 700	None	1.15A	1fmlB-3b2rA: undetectable	1fmlB-3b2rA: 20.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 9	TYR A 612 LEU A 725 LEU A 765 VAL A 782 ALA A 783 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.36A	1tbfA-3b2rA: 45.7	1tbfA-3b2rA: 94.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1TDR_B_MTXB170_1 (TELLUROMETHIONYL DIHYDROFOLATE REDUCTASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	ALA A 572 LEU A 651 ILE A 692 LEU A 655 THR A 571	None	1.42A	1tdrB-3b2rA: undetectable	1tdrB-3b2rA: 17.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDT_A_VIAA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.36A	1udtA-3b2rA: 46.1	1udtA-3b2rA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDU_A_CIAA1003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 11	TYR A 612 ILE A 778 VAL A 782 ALA A 783 PHE A 786 ILE A 813 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) None VDN A 1 ( 4.2A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.74A	1uduA-3b2rA: 43.4	1uduA-3b2rA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDU_B_CIAB2003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 612 ALA A 767 ILE A 768 GLN A 775 ILE A 778 VAL A 782 ALA A 783 PHE A 786 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.4A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) None VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.60A	1uduB-3b2rA: 43.4	1uduB-3b2rA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 10	TYR A 612 HIS A 613 ALA A 783 PHE A 786 MET A 816 GLN A 817 GLY A 819 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 4.0A) None VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 ( 4.1A) VDN A 1 (-3.6A)	0.42A	1uhoA-3b2rA: 46.0	1uhoA-3b2rA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 612 HIS A 613 HIS A 657 LEU A 765 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.96A	1xlxA-3b2rA: 30.9	1xlxA-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 612 HIS A 613 HIS A 657 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.84A	1xlxB-3b2rA: 30.8	1xlxB-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) None VDN A 1 (-3.6A)	0.77A	1xmuA-3b2rA: 31.0	1xmuA-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) None	0.73A	1xmuB-3b2rA: 31.0	1xmuB-3b2rA: 28.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 775	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.4A)	1.00A	1xomA-3b2rA: 31.5	1xomA-3b2rA: 31.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.65A	1xomA-3b2rA: 31.5	1xomA-3b2rA: 31.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 612 HIS A 613 LEU A 765 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 4.7A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.68A	1xomB-3b2rA: 31.6	1xomB-3b2rA: 31.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.6A)	0.67A	1xoqA-3b2rA: 31.6	1xoqA-3b2rA: 31.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.6A)	0.68A	1xoqB-3b2rA: 31.7	1xoqB-3b2rA: 31.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 775	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.4A)	0.94A	1xosA-3b2rA: 31.1	1xosA-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 786 GLN A 817 PHE A 820 ILE A 824	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A) None	0.65A	1xosA-3b2rA: 31.1	1xosA-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 612 HIS A 613 LEU A 765 GLN A 817 PHE A 820 ILE A 824	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 4.7A) VDN A 1 (-3.0A) VDN A 1 (-3.6A) None	0.58A	1xotA-3b2rA: 31.0	1xotA-3b2rA: 28.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 LEU A 765 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 4.7A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.59A	1xotB-3b2rA: 31.1	1xotB-3b2rA: 28.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOZ_A_CIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 612 ALA A 767 ILE A 768 GLN A 775 ILE A 778 VAL A 782 PHE A 786 ILE A 813 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.4A) None VDN A 1 ( 4.7A) None VDN A 1 ( 4.2A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.53A	1xozA-3b2rA: 45.7	1xozA-3b2rA: 94.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XP0_A_VDNA201_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 10	TYR A 612 LEU A 765 ALA A 767 ILE A 768 VAL A 782 ALA A 783 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 ( 4.7A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.28A	1xp0A-3b2rA: 45.9	1xp0A-3b2rA: 94.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XZX_X_T3X500_1 (THYROID HORMONE RECEPTOR BETA-1)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ILE A 715 ALA A 719 MET A 760 LEU A 756 LEU A 629	None	1.09A	1xzxX-3b2rA: undetectable	1xzxX-3b2rA: 21.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EJF_A_ADNA2001_1 (235AA LONG HYPOTHETICAL BIOTIN--[ACETYL-COA- CARBOXYLASE] LIGASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	ARG A 538 GLU A 539 ALA A 545 ALA A 544	None	1.04A	2ejfA-3b2rA: undetectable	2ejfA-3b2rA: 20.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	9 / 11	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 PHE A 786 ILE A 813 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.7A) None VDN A 1 ( 4.2A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.47A	2h42A-3b2rA: 46.2	2h42A-3b2rA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	10 / 12	TYR A 612 HIS A 613 ALA A 767 ILE A 768 VAL A 782 ALA A 783 ILE A 813 MET A 816 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) VDN A 1 ( 4.2A) VDN A 1 (-4.0A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.36A	2h42B-3b2rA: 46.2	2h42B-3b2rA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 612 LEU A 725 LEU A 765 ALA A 767 ILE A 768 VAL A 782 ALA A 783 PHE A 786 ILE A 813 GLN A 817 PHE A 820	VDN A 1 (-4.8A) None VDN A 1 ( 4.7A) VDN A 1 ( 3.8A) VDN A 1 (-4.5A) VDN A 1 ( 4.7A) VDN A 1 ( 4.0A) None VDN A 1 ( 4.2A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.41A	2h42C-3b2rA: 46.6	2h42C-3b2rA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q72_A_IXXA802_1 (TRANSPORTER)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	ILE A 599 ARG A 577 ILE A 556 PHE A 619	None	1.10A	2q72A-3b2rA: undetectable	2q72A-3b2rA: 20.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2QB4_A_DSMA802_1 (TRANSPORTER)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	ILE A 599 ARG A 577 ILE A 556 PHE A 619	None	1.10A	2qb4A-3b2rA: undetectable	2qb4A-3b2rA: 20.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2QO4_A_CHDA130_0 (LIVER-BASIC FATTY ACID BINDING PROTEIN)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	LEU A 842 ALA A 628 THR A 761 MET A 760 HIS A 617	None	1.33A	2qo4A-3b2rA: undetectable	2qo4A-3b2rA: 17.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 612 HIS A 613 LEU A 725 LEU A 765 GLU A 785 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) None None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.81A	2weyA-3b2rA: 36.5	2weyA-3b2rA: 38.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	LEU A 725 PHE A 786 GLN A 817 PHE A 820	None None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.52A	2weyB-3b2rA: 36.2	2weyB-3b2rA: 38.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3D90_B_NOGB2001_1 (PROGESTERONE RECEPTOR)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	LEU A 647 LEU A 644 LEU A 641 LEU A 595 MET A 590	None	1.32A	3d90B-3b2rA: 3.4	3d90B-3b2rA: 22.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3E22_B_LOCB700_2 (TUBULIN BETA-2B CHAIN)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	CYH A 596 LEU A 600 ALA A 572 LEU A 569 ALA A 546	None	1.04A	3e22B-3b2rA: undetectable	3e22B-3b2rA: 20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3E22_D_LOCD700_2 (TUBULIN BETA-2B CHAIN)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	CYH A 596 LEU A 600 ALA A 572 LEU A 569 ALA A 546	None	1.06A	3e22D-3b2rA: undetectable	3e22D-3b2rA: 20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FL9_A_TOPA200_1 (DIHYDROFOLATE REDUCTASE (DHFR))	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	ALA A 618 VAL A 602 ALA A 719 ILE A 716 LEU A 693	None	1.18A	3fl9A-3b2rA: undetectable	3fl9A-3b2rA: 19.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	ASP A 764 LEU A 765 GLN A 775	None VDN A 1 ( 4.7A) VDN A 1 ( 4.4A)	0.68A	3g4lA-3b2rA: 31.3	3g4lA-3b2rA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	ASP A 764 LEU A 765 GLN A 817	None VDN A 1 ( 4.7A) VDN A 1 (-3.0A)	0.50A	3g4lA-3b2rA: 31.3	3g4lA-3b2rA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.6A)	0.61A	3g4lB-3b2rA: 31.6	3g4lB-3b2rA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 775	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 ( 4.4A)	1.02A	3g4lD-3b2rA: 31.9	3g4lD-3b2rA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 612 HIS A 613 ASP A 764 LEU A 765 GLN A 817	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.0A)	0.55A	3g4lD-3b2rA: 31.9	3g4lD-3b2rA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GWS_X_T3X500_1 (THYROID HORMONE RECEPTOR BETA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ILE A 715 ALA A 719 MET A 760 LEU A 756 LEU A 629	None	1.04A	3gwsX-3b2rA: undetectable	3gwsX-3b2rA: 21.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 612 PHE A 786 GLN A 817 PHE A 820 ILE A 824	VDN A 1 (-4.8A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A) None	0.40A	3iakA-3b2rA: 30.8	3iakA-3b2rA: 31.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 612 HIS A 613 LEU A 725 VAL A 782 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 4.7A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.42A	3jwqA-3b2rA: 45.0	3jwqA-3b2rA: 93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 VAL A 782 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 3.8A) VDN A 1 ( 4.7A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.40A	3jwqB-3b2rA: 44.9 3jwqC-3b2rA: 44.9	3jwqB-3b2rA: 93.33 3jwqC-3b2rA: 93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	TYR A 612 HIS A 613 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.46A	3jwqC-3b2rA: 44.9	3jwqC-3b2rA: 93.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 612 HIS A 613 LEU A 725 ALA A 767 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) VDN A 1 (-4.3A) None VDN A 1 ( 3.8A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.52A	3jwqA-3b2rA: 45.0 3jwqD-3b2rA: 44.6	3jwqA-3b2rA: 93.33 3jwqD-3b2rA: 93.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 7	TYR A 612 PHE A 786 GLN A 817 PHE A 820	VDN A 1 (-4.8A) None VDN A 1 (-3.0A) VDN A 1 (-3.6A)	0.53A	3tvxB-3b2rA: 31.6	3tvxB-3b2rA: 29.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UJ7_A_SAMA301_1 (PHOSPHOETHANOLAMINE N-METHYLTRANSFERASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	SER A 766 ASP A 563 ASP A 568	None	0.90A	3uj7A-3b2rA: undetectable	3uj7A-3b2rA: 23.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DFB_B_KANB401_1 (APH(2')-ID)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	ASP A 764 ASP A 654 HIS A 653 GLU A 785 GLU A 682	None	0.89A	4dfbB-3b2rA: 1.0	4dfbB-3b2rA: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DFU_B_KANB402_1 (APH(2')-ID)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ASP A 764 ASP A 654 HIS A 653 GLU A 785 GLU A 682	None	0.94A	4dfuB-3b2rA: 2.3	4dfuB-3b2rA: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZ7_A_1E8A901_1 (CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	ILE A 576 THR A 712 ILE A 648 PHE A 588 LEU A 651	None	0.96A	4rz7A-3b2rA: undetectable	4rz7A-3b2rA: 18.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_A_X6XA202_1 (GALNAC/GAL-SPECIFIC LECTIN)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 8	GLU A 785 GLY A 659 VAL A 610 HIS A 613 HIS A 684	None None None VDN A 1 (-4.3A) None	1.30A	5f8yA-3b2rA: undetectable	5f8yA-3b2rA: 16.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_B_X6XB201_1 (GALNAC/GAL-SPECIFIC LECTIN)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 8	GLU A 785 GLY A 659 VAL A 610 HIS A 613 HIS A 684	None None None VDN A 1 (-4.3A) None	1.34A	5f8yB-3b2rA: undetectable	5f8yB-3b2rA: 16.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NCD_A_ACTA301_0 (PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	ASP A 654 HIS A 613 HIS A 617 HIS A 684	None VDN A 1 (-4.3A) None None	0.80A	5ncdA-3b2rA: undetectable 5ncdD-3b2rA: undetectable	5ncdA-3b2rA: 21.92 5ncdD-3b2rA: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NCD_C_ACTC301_0 (PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	ASP A 654 HIS A 613 HIS A 617 HIS A 684	None VDN A 1 (-4.3A) None None	0.81A	5ncdB-3b2rA: undetectable 5ncdC-3b2rA: undetectable	5ncdB-3b2rA: 21.92 5ncdC-3b2rA: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NEK_B_AZMB302_1 (PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	ASP A 654 HIS A 613 HIS A 617 HIS A 684	None VDN A 1 (-4.3A) None None	0.90A	5nekB-3b2rA: undetectable	5nekB-3b2rA: 15.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NEK_D_AZMD302_1 (PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	ASP A 654 HIS A 613 HIS A 617 HIS A 684	None VDN A 1 (-4.3A) None None	0.85A	5nekD-3b2rA: undetectable	5nekD-3b2rA: 15.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NEL_A_ACTA302_0 (PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	ASP A 654 HIS A 613 HIS A 617 HIS A 684	None VDN A 1 (-4.3A) None None	0.87A	5nelA-3b2rA: undetectable 5nelD-3b2rA: undetectable	5nelA-3b2rA: 21.92 5nelD-3b2rA: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NFJ_A_SAMA501_0 (MITOCHONDRIAL RIBONUCLEASE P PROTEIN 1)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	LEU A 573 ILE A 576 LEU A 569 LEU A 600 LEU A 595	None	0.99A	5nfjA-3b2rA: undetectable	5nfjA-3b2rA: 20.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NFP_A_8W5A804_2 (GLUCOCORTICOID RECEPTOR)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 4	LEU A 646 MET A 578 ILE A 716 LEU A 651	None	1.30A	5nfpA-3b2rA: 3.7	5nfpA-3b2rA: 24.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OEX_B_CUB601_0 (THIOCYANATE DEHYDROGENASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	HIS A 684 ASP A 654 HIS A 613	None None VDN A 1 (-4.3A)	0.79A	5oexB-3b2rA: undetectable	5oexB-3b2rA: 19.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OEX_D_CUD601_0 (THIOCYANATE DEHYDROGENASE)	3b2r	CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	HIS A 684 ASP A 654 HIS A 613	None None VDN A 1 (-4.3A)	0.76A	5oexD-3b2rA: undetectable	5oexD-3b2rA: 19.40

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1BZM_A_MZMA262_1","CARBONIC ANHYDRASE I","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"PHE A 820;HIS A 653;THR A 621;HIS A 617","VDN A   1 (-3.6A);None;None;None","0.97A","1bzmA-3b2rA:undetectable","1bzmA-3b2rA:20.71"],["1EI6_A_PPFA410_1","PHOSPHONOACETATE HYDROLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"THR A 723;ASP A 654;HIS A 613;HIS A 684","None;None;VDN A   1 (-4.3A);None","0.99A","1ei6A-3b2rA:undetectable","1ei6A-3b2rA:22.25"],["1FML_B_RTLB501_0","RETINOL DEHYDRATASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 716;LEU A 651;SER A 652;LEU A 701;ILE A 700","None","1.15A","1fmlB-3b2rA:undetectable","1fmlB-3b2rA:20.97"],["1TBF_A_VIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 612;LEU A 725;LEU A 765;VAL A 782;ALA A 783;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.36A","1tbfA-3b2rA:45.7","1tbfA-3b2rA:94.24"],["1TDR_B_MTXB170_1","TELLUROMETHIONYL DIHYDROFOLATE REDUCTASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ALA A 572;LEU A 651;ILE A 692;LEU A 655;THR A 571","None","1.42A","1tdrB-3b2rA:undetectable","1tdrB-3b2rA:17.93"],["1UDT_A_VIAA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",9,"TYR A 612;HIS A 613;ALA A 767;ILE A 768;VAL A 782;ALA A 783;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.36A","1udtA-3b2rA:46.1","1udtA-3b2rA:100.00"],["1UDU_A_CIAA1003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",9,"TYR A 612;ILE A 778;VAL A 782;ALA A 783;PHE A 786;ILE A 813;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);None;VDN A   1 ( 4.2A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.74A","1uduA-3b2rA:43.4","1uduA-3b2rA:100.00"],["1UDU_B_CIAB2003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",11,"TYR A 612;ALA A 767;ILE A 768;GLN A 775;ILE A 778;VAL A 782;ALA A 783;PHE A 786;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.4A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);None;VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.60A","1uduB-3b2rA:43.4","1uduB-3b2rA:100.00"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 612;HIS A 613;ALA A 783;PHE A 786;MET A 816;GLN A 817;GLY A 819;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 4.0A);None;VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 ( 4.1A);VDN A   1 (-3.6A)","0.42A","1uhoA-3b2rA:46.0","1uhoA-3b2rA:100.00"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;HIS A 657;LEU A 765;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.96A","1xlxA-3b2rA:30.9","1xlxA-3b2rA:28.16"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;HIS A 657;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.84A","1xlxB-3b2rA:30.8","1xlxB-3b2rA:28.16"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 786;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);None;VDN A   1 (-3.6A)","0.77A","1xmuA-3b2rA:31.0","1xmuA-3b2rA:28.16"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 786","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);None","0.73A","1xmuB-3b2rA:31.0","1xmuB-3b2rA:28.16"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;GLN A 775","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.4A)","1.00A","1xomA-3b2rA:31.5","1xomA-3b2rA:31.23"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.65A","1xomA-3b2rA:31.5","1xomA-3b2rA:31.23"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;LEU A 765;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 4.7A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.68A","1xomB-3b2rA:31.6","1xomB-3b2rA:31.23"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.6A)","0.67A","1xoqA-3b2rA:31.6","1xoqA-3b2rA:31.23"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.6A)","0.68A","1xoqB-3b2rA:31.7","1xoqB-3b2rA:31.23"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;GLN A 775","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.4A)","0.94A","1xosA-3b2rA:31.1","1xosA-3b2rA:28.16"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 786;GLN A 817;PHE A 820;ILE A 824","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A);None","0.65A","1xosA-3b2rA:31.1","1xosA-3b2rA:28.16"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;LEU A 765;GLN A 817;PHE A 820;ILE A 824","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 4.7A);VDN A   1 (-3.0A);VDN A   1 (-3.6A);None","0.58A","1xotA-3b2rA:31.0","1xotA-3b2rA:28.16"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;LEU A 765;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 4.7A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.59A","1xotB-3b2rA:31.1","1xotB-3b2rA:28.16"],["1XOZ_A_CIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",11,"TYR A 612;ALA A 767;ILE A 768;GLN A 775;ILE A 778;VAL A 782;PHE A 786;ILE A 813;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.4A);None;VDN A   1 ( 4.7A);None;VDN A   1 ( 4.2A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.53A","1xozA-3b2rA:45.7","1xozA-3b2rA:94.28"],["1XP0_A_VDNA201_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",9,"TYR A 612;LEU A 765;ALA A 767;ILE A 768;VAL A 782;ALA A 783;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 ( 4.7A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.28A","1xp0A-3b2rA:45.9","1xp0A-3b2rA:94.28"],["1XZX_X_T3X500_1","THYROID HORMONE RECEPTOR BETA-1","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 715;ALA A 719;MET A 760;LEU A 756;LEU A 629","None","1.09A","1xzxX-3b2rA:undetectable","1xzxX-3b2rA:21.05"],["2EJF_A_ADNA2001_1","235AA LONG HYPOTHETICAL BIOTIN--[ACETYL-COA-CARBOXYLASE] LIGASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ARG A 538;GLU A 539;ALA A 545;ALA A 544","None","1.04A","2ejfA-3b2rA:undetectable","2ejfA-3b2rA:20.12"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",9,"TYR A 612;HIS A 613;ALA A 767;ILE A 768;VAL A 782;PHE A 786;ILE A 813;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.7A);None;VDN A   1 ( 4.2A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.47A","2h42A-3b2rA:46.2","2h42A-3b2rA:100.00"],["2H42_B_VIAB902_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",10,"TYR A 612;HIS A 613;ALA A 767;ILE A 768;VAL A 782;ALA A 783;ILE A 813;MET A 816;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);VDN A   1 ( 4.2A);VDN A   1 (-4.0A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.36A","2h42B-3b2rA:46.2","2h42B-3b2rA:100.00"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",11,"TYR A 612;LEU A 725;LEU A 765;ALA A 767;ILE A 768;VAL A 782;ALA A 783;PHE A 786;ILE A 813;GLN A 817;PHE A 820","VDN A   1 (-4.8A);None;VDN A   1 ( 4.7A);VDN A   1 ( 3.8A);VDN A   1 (-4.5A);VDN A   1 ( 4.7A);VDN A   1 ( 4.0A);None;VDN A   1 ( 4.2A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.41A","2h42C-3b2rA:46.6","2h42C-3b2rA:100.00"],["2Q72_A_IXXA802_1","TRANSPORTER","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ILE A 599;ARG A 577;ILE A 556;PHE A 619","None","1.10A","2q72A-3b2rA:undetectable","2q72A-3b2rA:20.49"],["2QB4_A_DSMA802_1","TRANSPORTER","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ILE A 599;ARG A 577;ILE A 556;PHE A 619","None","1.10A","2qb4A-3b2rA:undetectable","2qb4A-3b2rA:20.49"],["2QO4_A_CHDA130_0","LIVER-BASIC FATTY ACID BINDING PROTEIN","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"LEU A 842;ALA A 628;THR A 761;MET A 760;HIS A 617","None","1.33A","2qo4A-3b2rA:undetectable","2qo4A-3b2rA:17.79"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 612;HIS A 613;LEU A 725;LEU A 765;GLU A 785;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);None;None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.81A","2weyA-3b2rA:36.5","2weyA-3b2rA:38.81"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"LEU A 725;PHE A 786;GLN A 817;PHE A 820","None;None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.52A","2weyB-3b2rA:36.2","2weyB-3b2rA:38.81"],["3D90_B_NOGB2001_1","PROGESTERONE RECEPTOR","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"LEU A 647;LEU A 644;LEU A 641;LEU A 595;MET A 590","None","1.32A","3d90B-3b2rA:3.4","3d90B-3b2rA:22.66"],["3E22_B_LOCB700_2","TUBULIN BETA-2B CHAIN","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"CYH A 596;LEU A 600;ALA A 572;LEU A 569;ALA A 546","None","1.04A","3e22B-3b2rA:undetectable","3e22B-3b2rA:20.68"],["3E22_D_LOCD700_2","TUBULIN BETA-2B CHAIN","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"CYH A 596;LEU A 600;ALA A 572;LEU A 569;ALA A 546","None","1.06A","3e22D-3b2rA:undetectable","3e22D-3b2rA:20.68"],["3FL9_A_TOPA200_1","DIHYDROFOLATE REDUCTASE (DHFR)","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ALA A 618;VAL A 602;ALA A 719;ILE A 716;LEU A 693","None","1.18A","3fl9A-3b2rA:undetectable","3fl9A-3b2rA:19.94"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"ASP A 764;LEU A 765;GLN A 775","None;VDN A   1 ( 4.7A);VDN A   1 ( 4.4A)","0.68A","3g4lA-3b2rA:31.3","3g4lA-3b2rA:27.78"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"ASP A 764;LEU A 765;GLN A 817","None;VDN A   1 ( 4.7A);VDN A   1 (-3.0A)","0.50A","3g4lA-3b2rA:31.3","3g4lA-3b2rA:27.78"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.6A)","0.61A","3g4lB-3b2rA:31.6","3g4lB-3b2rA:27.78"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;GLN A 775","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 ( 4.4A)","1.02A","3g4lD-3b2rA:31.9","3g4lD-3b2rA:27.78"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;HIS A 613;ASP A 764;LEU A 765;GLN A 817","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.0A)","0.55A","3g4lD-3b2rA:31.9","3g4lD-3b2rA:27.78"],["3GWS_X_T3X500_1","THYROID HORMONE RECEPTOR BETA","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 715;ALA A 719;MET A 760;LEU A 756;LEU A 629","None","1.04A","3gwsX-3b2rA:undetectable","3gwsX-3b2rA:21.30"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 612;PHE A 786;GLN A 817;PHE A 820;ILE A 824","VDN A   1 (-4.8A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A);None","0.40A","3iakA-3b2rA:30.8","3iakA-3b2rA:31.23"],["3JWQ_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 612;HIS A 613;LEU A 725;VAL A 782;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 4.7A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.42A","3jwqA-3b2rA:45.0","3jwqA-3b2rA:93.33"],["3JWQ_B_VIAB901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 612;HIS A 613;LEU A 725;ALA A 767;VAL A 782;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 3.8A);VDN A   1 ( 4.7A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.40A","3jwqB-3b2rA:44.9;3jwqC-3b2rA:44.9","3jwqB-3b2rA:93.33;3jwqC-3b2rA:93.33"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"TYR A 612;HIS A 613;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.46A","3jwqC-3b2rA:44.9","3jwqC-3b2rA:93.33"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 612;HIS A 613;LEU A 725;ALA A 767;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);VDN A   1 (-4.3A);None;VDN A   1 ( 3.8A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.52A","3jwqA-3b2rA:45.0;3jwqD-3b2rA:44.6","3jwqA-3b2rA:93.33;3jwqD-3b2rA:93.33"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"TYR A 612;PHE A 786;GLN A 817;PHE A 820","VDN A   1 (-4.8A);None;VDN A   1 (-3.0A);VDN A   1 (-3.6A)","0.53A","3tvxB-3b2rA:31.6","3tvxB-3b2rA:29.39"],["3UJ7_A_SAMA301_1","PHOSPHOETHANOLAMINE N-METHYLTRANSFERASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"SER A 766;ASP A 563;ASP A 568","None","0.90A","3uj7A-3b2rA:undetectable","3uj7A-3b2rA:23.69"],["4DFB_B_KANB401_1","APH(2')-ID","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ASP A 764;ASP A 654;HIS A 653;GLU A 785;GLU A 682","None","0.89A","4dfbB-3b2rA:1.0","4dfbB-3b2rA:23.98"],["4DFU_B_KANB402_1","APH(2')-ID","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ASP A 764;ASP A 654;HIS A 653;GLU A 785;GLU A 682","None","0.94A","4dfuB-3b2rA:2.3","4dfuB-3b2rA:23.98"],["4RZ7_A_1E8A901_1","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 576;THR A 712;ILE A 648;PHE A 588;LEU A 651","None","0.96A","4rz7A-3b2rA:undetectable","4rz7A-3b2rA:18.05"],["5F8Y_A_X6XA202_1","GALNAC\/GAL-SPECIFIC LECTIN","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"GLU A 785;GLY A 659;VAL A 610;HIS A 613;HIS A 684","None;None;None;VDN A   1 (-4.3A);None","1.30A","5f8yA-3b2rA:undetectable","5f8yA-3b2rA:16.41"],["5F8Y_B_X6XB201_1","GALNAC\/GAL-SPECIFIC LECTIN","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"GLU A 785;GLY A 659;VAL A 610;HIS A 613;HIS A 684","None;None;None;VDN A   1 (-4.3A);None","1.34A","5f8yB-3b2rA:undetectable","5f8yB-3b2rA:16.41"],["5NCD_A_ACTA301_0","PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 654;HIS A 613;HIS A 617;HIS A 684","None;VDN A   1 (-4.3A);None;None","0.80A","5ncdA-3b2rA:undetectable;5ncdD-3b2rA:undetectable","5ncdA-3b2rA:21.92;5ncdD-3b2rA:21.92"],["5NCD_C_ACTC301_0","PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 654;HIS A 613;HIS A 617;HIS A 684","None;VDN A   1 (-4.3A);None;None","0.81A","5ncdB-3b2rA:undetectable;5ncdC-3b2rA:undetectable","5ncdB-3b2rA:21.92;5ncdC-3b2rA:21.92"],["5NEK_B_AZMB302_1","PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 654;HIS A 613;HIS A 617;HIS A 684","None;VDN A   1 (-4.3A);None;None","0.90A","5nekB-3b2rA:undetectable","5nekB-3b2rA:15.00"],["5NEK_D_AZMD302_1","PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 654;HIS A 613;HIS A 617;HIS A 684","None;VDN A   1 (-4.3A);None;None","0.85A","5nekD-3b2rA:undetectable","5nekD-3b2rA:15.00"],["5NEL_A_ACTA302_0","PEPTIDOGLYCAN N-ACETYLGLUCOSAMINE DEACETYLASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 654;HIS A 613;HIS A 617;HIS A 684","None;VDN A   1 (-4.3A);None;None","0.87A","5nelA-3b2rA:undetectable;5nelD-3b2rA:undetectable","5nelA-3b2rA:21.92;5nelD-3b2rA:21.92"],["5NFJ_A_SAMA501_0","MITOCHONDRIAL RIBONUCLEASE P PROTEIN 1","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"LEU A 573;ILE A 576;LEU A 569;LEU A 600;LEU A 595","None","0.99A","5nfjA-3b2rA:undetectable","5nfjA-3b2rA:20.49"],["5NFP_A_8W5A804_2","GLUCOCORTICOID RECEPTOR","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"LEU A 646;MET A 578;ILE A 716;LEU A 651","None","1.30A","5nfpA-3b2rA:3.7","5nfpA-3b2rA:24.09"],["5OEX_B_CUB601_0","THIOCYANATE DEHYDROGENASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"HIS A 684;ASP A 654;HIS A 613","None;None;VDN A   1 (-4.3A)","0.79A","5oexB-3b2rA:undetectable","5oexB-3b2rA:19.40"],["5OEX_D_CUD601_0","THIOCYANATE DEHYDROGENASE","3b2r","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"HIS A 684;ASP A 654;HIS A 613","None;None;VDN A   1 (-4.3A)","0.76A","5oexD-3b2rA:undetectable","5oexD-3b2rA:19.40"]]